Concomitant continuous infusion chemotherapy and radiation
Journal Article
·
· Cancer (Philadelphia); (USA)
DOI:https://doi.org/10.1002/1097-0142(19900201)65:3+<823::AID-CNCR2820651330>3.0.CO;2-9·
OSTI ID:6809192
- State Univ. of New York, Brooklyn (USA)
Attempts to duplicate the cytotoxic effect of oxygen on radioresistant tissues spurred a search by radiation oncologists for other radiosensitizing techniques. This led to large-scale investigations using neutrons and other heavy particle radiations, hyperthermia, altered fractionation schedules, and the systemic use of the halogenated pyrimidines and the electron-affinic compounds. Unfortunately, the promise that the nitroimidazole compounds would selectively sensitize the radioresistant tumor cells and prove to be an effective systemic agent has not been borne out in clinical trials thus far. Existing pharmokinetic and cytokinetic studies have suggested that continuous infusion chemotherapy given concomitantly (CCIC) with irradiation (RT) acts synergistically, resulting in a significant increase in tumor cell killing. These observations have been supported by clinical research studies treating certain epithelial cancers that have resulted in considerably higher locoregional control rates and improved survival. Although initially used in treatment of only advanced or inoperable epithelial carcinomas, CCIC and RT are now being employed in the treatment of lower staged cancers as an organ-sparing procedure. Carcinoma of the anus treated by anteroposterior (AP) resection alone have reported 5-year survival rates of 30% to 60%. CCIC and RT using 5-fluorouracil (5-FU) and mitomycin C have achieved a local control rate of 90% to 100% and a 5-year survival rate of 80% to 86% with sphincter preservation in 90% of these cases. The 5-year survival rate in advanced urinary bladder carcinoma is 25% to 30% for either radiation or surgery and 42% when combined in a preoperative radiation schedule. Using 5-FU CCIC and RT, the local control rate of transitional cell carcinoma of the bladder has been 71% to 86% with a 5-year survival of 62%. 102 references.
- OSTI ID:
- 6809192
- Journal Information:
- Cancer (Philadelphia); (USA), Journal Name: Cancer (Philadelphia); (USA) Vol. 65; ISSN 0008-543X; ISSN CANCA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Preoperative Capecitabine and Pelvic Radiation in Locally Advanced Rectal Cancer-Is it Equivalent to 5-FU Infusion Plus Leucovorin and Radiotherapy?
Clinical applications of continuous infusion chemotherapy ahd concomitant radiation therapy
Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial
Journal Article
·
Thu Apr 15 00:00:00 EDT 2010
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21372206
Clinical applications of continuous infusion chemotherapy ahd concomitant radiation therapy
Conference
·
Tue Dec 31 23:00:00 EST 1985
·
OSTI ID:6853060
Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial
Journal Article
·
Mon Jun 01 00:00:00 EDT 2009
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21276831